Table of contents

Ovarian Cancer

• Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study (30 April, 2021)

  Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Simona Frezzini, Germana Tognon, Grazia Artioli, Angiolo Gadducci, Rossella Lauria, Annamaria Ferrero, Saverio Cinieri, Andrea De Censi, Enrico Breda, Paolo Scollo, Ugo De Giorgi, Andrea Alberto Lissoni, Dionyssios Katsaros, Domenica Lorusso, Vanda Salutari, Sabrina Chiara Cecere, Eleonora Zaccarelli, Margherita Nardin, Giorgio Bogani, Mariagrazia Distefano, Stefano Greggi, Maria Carmela Piccirillo, Roldano Fossati, Gaia Giannone, Laura Arenare, Ciro Gallo, Francesco Perrone, Sandro Pignata
• Feasibility of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer during COVID-19 pandemic (15 April, 2021)

  Ali Ayhan, Safak Yilmaz Baran, Dogan Vatansever, Gulsen Dogan Durdag, Huseyin Akilli, Husnu Celik, Cagatay Taskiran
• Practice patterns in post-treatment surveillance in patients with primary epithelial ovarian cancer (5 August, 2020)

  Joseph DeMari, Monica Hagan Vetter, Shruthi Chandra, John L Hays, Ritu Salani
• Role of inhibin B in detecting recurrence of granulosa cell tumors of the ovary in postmenopausal patients (23 April, 2021)

  Rosalba Portuesi, Alessandro Loppini, Rosanna Mancari, Simonetta Filippi, Nicoletta Colombo